Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104022
Filing Date
2025-08-06
Accepted
2025-08-06 16:11:01
Documents
77
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvmd-20250630.htm   iXBRL 10-Q 3268152
2 EX-10.1 rvmd-ex10_1.htm EX-10.1 662523
3 EX-10.2 rvmd-ex10_2.htm EX-10.2 1254092
4 EX-31.1 rvmd-ex31_1.htm EX-31.1 17210
5 EX-31.2 rvmd-ex31_2.htm EX-31.2 17169
6 EX-32.1 rvmd-ex32_1.htm EX-32.1 9088
7 EX-32.2 rvmd-ex32_2.htm EX-32.2 9078
  Complete submission text file 0000950170-25-104022.txt   13855317

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rvmd-20250630.xsd EX-101.SCH 1164413
79 EXTRACTED XBRL INSTANCE DOCUMENT rvmd-20250630_htm.xml XML 2453526
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39219 | Film No.: 251189659
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)